In a NOLA.com guest column, Vidrine asks Sen. Bill Cassidy and FDA nominee Heidi Overton to tackle social media algorithms pushing unregulated injectables to minors.
Recap by typeshit. Full story at NOLA.com.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
The review covers how GLP-1 drugs touch metabolic, inflammatory and nerve survival pathways tied to Parkinson's. Protective effects so far come from lab and animal models.
The proposal would let the FDA hold off on enforcement for certain peptides. FDA staff scientists found none proven safe or effective, and CSPI is pushing back.
Loading…